Concert Pharma

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to report 2021 financial results before the markets open on March 3, 2022.

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.

Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's on-demand fireside chat at the Jefferies London conference will be available beginning at 8:00 a.m. GMT on November 18, 2021.

Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences

Clear Channel Outdoor Holdings

ReTo Eco-Solutions

Check these penny stocks out for your watchlist in November The post Are These Penny Stocks Worth Being Bullish On? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks Worth Being Bullish On? 3 to Watch

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2021 Results - Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the third quarter of 2021.

Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

Artelo Biosciences Inc

TDH Hlds

Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Trending Penny Stocks Worth Buying at Current Levels?

The stock price of Concert Pharmaceuticals Inc (NASDAQ: CNCE) increased 27.43% today. This is why it happened.

Concert Pharmaceuticals (CNCE) Stock: Why The Price Surged Today

IT Tech Packaging Inc

Are these penny stocks on your November watchlist? The post Why These Penny Stocks Popped Today, 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why These Penny Stocks Popped Today, 3 to Watch

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals entered into an agreement with BVF Partners and RA Capital to raise gross proceeds of $65 million.

Concert Pharmaceuticals Announces $65 Million Financing

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to report third quarter 2021 financial results before the market open on November 9, 2021.

Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021

Earnings Preview: Concert Pharmaceuticals (CNCE) Q3 Earnings Expected to Decline

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert completed patient enrollment in the CTP-543 THRIVE-AA1 Phase 3 trial.

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--In September, Concert will present virtually at the HC Wainwright and Cantor healthcare conferences.

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2021 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the second quarter of 2021.

Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on August 5, 2021 to discuss its second quarter financial results and provide a business update.

Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021

Concert Pharmaceuticals Inc (NASDAQ: CNCE) has announced updated data from its ongoing open-label, long-term extension study of CTP-543 in patients with moderate to severe alopecia areata. Alopecia areata is an autoimmune disorder that results in patchy or complete hair loss.

Concert Pharma Sees US Application Submission For Patchy Hair Loss Candidate In 2023

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will provide an update on the CTP-543 open label, long-term extension study at the 2nd JAK Inhibitors Drug Development Summit.

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential NDA filing.

Concert (CNCE) Initiates Second Phase III Hair Loss Study

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA2 in the second half of 2022. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Concert--Concert announced that Vertex purchased the potential future milestones under their 2017 asset purchase agreement relating to VX-561 for $32 million.

News for Concert Pharma Stock (CNCE)